Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “multiple-myeloma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 167
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 167 pipeline programs matching "multiple-myeloma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

167 results for “multiple-myeloma” Back to intelligence hub

Search results

Page 1 of 7
  1. Belantamab mafodotin

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  2. Bortezomib

    Hospital Authority, Hong Kong

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  3. Carfilzomib

    Amgen

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials
  4. Cilta-cel

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  5. Dara SC

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  6. Daratumumab

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    3 trials
  7. Dexamethasone

    Amgen

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  8. Etoposide

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  9. Fosaprepitant

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  10. HM16/047

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  11. IGI, 10%

    Takeda

    Multiple Myeloma

    phase 3 mab active

    1 trial
  12. Ixazomib

    Takeda

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  13. Ixazomib Citrate

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials
  14. Linvoseltamab

    Regeneron UK Limited

    Multiple Myeloma (MM)

    phase 3 small molecule active

    1 trial
  15. Linvoseltamab

    Regeneron UK Limited

    Multiple Myeloma

    phase 3 small molecule active

    6 trials
  16. Linvoseltamab

    Regeneron UK Limited

    High Risk Smoldering Multiple Myeloma (HR-SMM)

    phase 3 small molecule active

    1 trial
  17. Linvoseltamab

    Regeneron UK Limited

    Relapsed Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    2 trials
  18. Linvoseltamab

    Regeneron UK Limited

    Relapsed and/or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial
  19. Melflufen

    Oncopeptides AB (publ)

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial
  20. MyelomaXIV

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial
  21. Panobinostat

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  22. Placebo

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial
  23. Placebo, Velcade and dexamethasone

    Centocor B.V.

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial
  24. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 3 small molecule active

    12 trials

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.